What is Multiple Myeloma Phase 2 Study Carfilzomib?

Category: Others

false

See also: Clinical Trial

NCT01402284 is a Phase 2, non-Randomized, open-label study of carfilzomib in combination with lenalidomide and dexamethasone in newly-diagnosed Multiple Myeloma. Carfilzomib is an experimental anti-cancer drug. Other Study IDs: 110221.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
0

Commonly reported side effects and conditions associated with Multiple Myeloma Phase 2 Study Carfilzomib

Side effect Patients
Anxious mood 1
Last updated:
There are no evaluations for Multiple Myeloma Phase 2 Study Carfilzomib.